Bristol-Myers Squibb diskutieren
Bristol-Myers Squibb
WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Aktie / Pharmazeutika / Large Cap /
50,10 €
0,73 %
Bristol-Myers Squibb (NYSE: BMY) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb Company (NYSE: BMY) had its price target lowered by analysts at Morgan Stanley from $36.00 to $34.00. They now have an "underweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $61.00 price target on the stock, up previously from $52.00.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $65.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $75.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (NYSE:BMY) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $75.00 price target on the stock, up previously from $66.00.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by UBS Group AG.
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by Guggenheim. They now have a $72.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Penske Automotive diskutieren